APP
URGN icon

Alpha Paradigm Partners’s UroGen Pharma URGN Stock Holding History

Alpha Paradigm Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31,028
Closed -$604K – 674
2021
Q1 		$604K Buy
+31,028
New +$659K 0.24% 132

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpha Paradigm Partners's URGN Position: Q2 2021 in Review

Alpha Paradigm Partners sold out of UroGen Pharma (URGN) in Q2 2021, closing a stake of 31,028 shares — an estimated $604K sold.

Alpha Paradigm Partners first reported a position in URGN in Q1 2021 and held it in 1 quarter. The position peaked at $604K in Q1 2021. 82 funds tracked by Wall St. Rank hold URGN as of Q2 2021.

  • Alpha Paradigm Partners reported no remaining UroGen Pharma position as of Q2 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 31,028 UroGen Pharma shares in Q2 2021, an estimated $604K.
  • Alpha Paradigm Partners first reported a position in UroGen Pharma in Q1 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's UroGen Pharma position peaked at $604K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2021.

Based on Alpha Paradigm Partners's 13F filing for Q2 2021, filed 13 Aug 2021.